Satellos is a biotechnology company dedicated to developing lifechanging medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. Satellos’ lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body’s innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients.
Ticker:
MSCL
Exchange:
TSXV
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2018
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
SME for Duchenne Muscular Dystrophy
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
